IMPACT OF MANGANESE ON AND TRANSFER ACROSS THE BLOOD-BRAIN AND BLOOD-CSF BARRIER IN VITRO

Julia Bornhorst1,2, Christoph A. Wehe3, Sabine Hüwel4, Uwe Karst3, Hans-Joachim Galla4, and Tanja Schwerdtle2*

1Graduate School of Chemistry, University of Münster, 48149 Münster, Germany
2Institute of Food Chemistry, University of Münster, 48149 Münster, Germany
3Institute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany
4Institute of Biochemistry, University of Münster, 48149 Münster, Germany

Running title: Manganese strongly affects blood-CSF barrier

*To whom correspondence should be addressed. Institute of Food Chemistry, University of Münster, Corrensstr. 45, 48149 Münster, Germany. Tel.: (49) -251-83-33874; Fax: (49) -251-83-33396; E-mail: tanja.schwerdtle@uni-muenster.de

Keywords: manganese; neurotoxicity; blood-brain barrier; blood-CSF barrier

Background: Modes of neurotoxic action after Mn-overexposure are not fully understood.

Results: The blood-CSF barrier showed higher Mn-sensitivity and active Mn-transport properties.

Conclusion: The blood-CSF barrier might be the major route for Mn into the brain.

Significance: Deeper insight in the impact of Mn on and its transfer across brain barrier systems might help to prevent irreversible neurological damage.

SUMMARY

Mn occupational and dietary overexposure has been shown to result in specific clinical central nervous system syndromes, which are similar to those observed in Parkinson’s disease. To date modes of neurotoxic action of Mn are still to be elucidated, but are thought to be strongly related to Mn accumulation in brain and oxidative stress. However, the pathway and the exact process of Mn uptake in the brain are yet not fully understood. Here, two well characterized primary porcine in vitro models of the blood-brain and the blood-CSF barrier were applied to assess the transfer of Mn in the brain while monitoring its effect on the barrier properties. Thus, for the first time effects of MnCl2 on the integrity of these two barriers as well as Mn transfer across the respective barriers were compared in one study. The data reveal a stronger Mn sensitivity of the in vitro blood-CSF barrier as compared to the blood-brain barrier. Very interestingly, the negative effects of Mn on the structural and functional properties of the highly Mn-sensitive blood-CSF barrier were partly reversible after postincubation with calcium. In summary, both the observed stronger Mn sensitivity of the in vitro blood-CSF barrier and the observed site directed, most probably active, Mn transport towards the brain facing compartment, reveal that, in contrast to the general assumption in literature, after oral Mn intake the blood-CSF barrier might be the major route for Mn into the brain.

Manganese (Mn) is an essential trace element required for normal growth development and cellular homeostasis (1). In the brain, Mn is of central importance as cofactor for a wide variety of enzymes, including arginase, pyruvate carboxylase, the antioxidant enzyme superoxide dismutase, as well as enzymes involved in neurotransmitter synthesis and metabolism. Very interestingly, an imbalance in Mn homeostasis caused by either Mn deficiency or overload is well known to result in severe CNS dysfunction. However, whereas Mn deficiency is extremely rare in humans, toxicity is more prevalent. Excessive brain Mn promotes potent neurotoxic effects with symptoms including tiredness, behavioral changes and delayed neurological disturbances characterized by dystonia or kinesia, resembling many clinical features of Parkinsonism but also distinct dissimilarities (2); the neurological phenotype is known as manganism (3). A primary source for Mn intoxication is the occupational exposure in miners, welders or workers in dry-cell battery factories. In addition, individuals receiving total parenteral nutrition, the contrast agent MnDPDP [also called manganese (II) N, N'-dipyridoxylethlenediamine-N, N'-diacetate-5, 5'-bis(phosphate); mangafodipirtri-sodium; TESLASCANTM], or drinking water with high levels of Mn are at higher risk for Mn intoxication; subtle pre-clinical neurological effects such as changes in cognitive abilities, short-term memory and motor control have been documented (4-7).
To date, the underlying mechanisms of Mn induced neurotoxicity are still to be elucidated. Several modes of action are discussed, among others oxidative stress, subsequent DNA damage and mitochondrial dysfunction in specific brain regions. Manganism is associated with elevated Mn levels in certain brain areas, namely caudate-putamen, globus pallidus, substantia nigra and subthalamic nucleus (8,9).

Brain manganese homeostasis is largely regulated by the blood-brain barrier (BBB) and blood-cerebrospinal fluid (CSF) barrier. The BBB separates blood from brain interstitial fluid (ISF) and consists basically of capillary endothelial cells connected by narrow tight junctions (TJ) which prevent paracellular flux processes. Moreover, recently it has become evident that the cells of the neurovascular unit, namely astrocytes, pericytes and neuronal cells are further essential for the induction and maintenance of the BBB properties (10). The second regulating system, the blood-CSF barrier is built up by the epithelial cells of the choroid plexus (CP) and separates blood from the cerebrospinal fluid. This epithelial barrier, which is sealed with TJ between the epithelial cells at the CSF-facing surface (apical surface) becomes indispensable since the endothelium of the CP is leaky and highly permeable. Despite the CSF secretion, as the best recognized feature of the CP, further CP functions include general brain homeostasis as well as defense of the brain against harmful substances (11).

Although Mn can cross the BBB and the blood-CSF barrier through several carriers in different oxidation states, the exact identity of the transporter(s) responsible as well as the process itself are still strongly debated. How Mn crosses the BBB has been a subject of many studies and it appears that several pathways are operative, including facilitated diffusion (12) and active transport. Mn is discussed to be transported among others via the divalent metal transporter 1 (DMT1), the transferrin (Tf) receptor (TfR), the divalent metal/bicarbonate ion symporters ZIP8 and ZIP14, various calcium channels, the solute carrier-39 (SLC39) family of zinc transporters, park9/ATP13A2, the magnesium transporter hip14, the transient receptor potential melastatin 7 (TRPM7) channels/transporters, homomeric purinreceptors (P2X and P2Y) and the citrate transporter (3,13-16).

In contrast, transfer of Mn across the blood-CSF barrier has been less studied. Proposed transporters include TfR, DMT1, metal transporter protein-1 (MTP1), Ca-channels or zinc-transporter (ZnT1, ZnT3, ZnT4 and ZnT6) (summarized in (16)).

Regarding the question of which Mn species enter the brain, Mn(II), Mn(II/III)citrate and Mn(III)transferrin are likely to be most relevant. Thereby, interestingly the Mn valence status might account for the transport properties at the respective barrier. While Mn(III) enters the brain via TIR-mediated mechanisms, Mn(II) is most likely readily taken up as free ion species or as a nonspecific protein-bound species (17,18).

In this work, two well characterized cell culture models of the BBB and the blood-CSF barrier were used to assess the transfer of Mn in the brain while monitoring its effect on the barrier properties. These two porcine based in vitro models allow for the first time a direct comparison of the effects of Mn on and the respective Mn-transfer across the BBB and the blood-CSF barrier. Thereby, also the different impacts on the barriers are illustrated when MnCl₂ is exposed from blood or brain facing sides. Furthermore, this paper indicates that the negative effects of Mn on the barrier properties of the highly Mn-sensitive blood-CSF barrier are partly reversible after treatment with Ca-enriched serum free medium.

EXPERIMENTAL PROCEDURES

Preparation of MnCl₂ and CaCl₂ stock solution – MnCl₂ (> 99.995 % purity) and CaCl₂ (> 99 % purity) (Sigma-Aldrich, Deisenhofen, Germany) stock solution were prepared in sterile bidistilled water. To prevent oxidation, stock solutions were prepared shortly before each experiment.

Isolation of primary porcine brain capillary endothelial and choroid plexus epithelial cells – Primary porcine brain capillary endothelial cells (PBCECs) were isolated, cultivated and cryopreserved as previously described (19). Primary porcine choroid plexus cells (PCPECs) were prepared as described before (20) with slight modifications. Briefly, choroid plexus tissue from freshly slaughtered pigs was incubated with 0.2 % trypsin at 4°C for 45 min and warmed to 37°C for 30 min. The release of the epithelial cells from the basal lamina was stopped by adding newborn bovine serum (Biochrom, Berlin, Germany). The cells were centrifuged at 20 g and resuspended in Dulbecco’s modified Eagle’s medium/Ham’s F 12 (1:1) supplemented with 10 % fetal bovine serum, 4 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin (all Biochrom, Berlin, Germany), 5 µg/mL insulin and 20 mM cytosine arabinoside (both Sigma-Aldrich, Deisenhofen, Germany). The nucleoside analog cytosine arabinoside supressed the growth of fibroblastic cells (21).

BBB cell culture model – PBCECs were gently thawed and seeded (250,000 /cm²) on rat tail (22)
collagen-coated (0.54 mg/mL) Transwell® filter inserts with microporous polycarbonate membranes (Corning, Wiesbaden, Germany, 1.12 cm² growth area, 0.4 µm pore size) on DIV2 in plating medium (Medium 199 Earle supplemented with 10% newborn calf serum, 0.7 mM L-glutamine, 100 µg/mL gentamycin, 100 U/mL penicillin, 100 µg/mL streptomycin (all Biochrom, Berlin, Germany)) in the apical compartment at 37°C with 5% CO₂ and 100% humidity. After PBCECs reached confluence (DIV4), the plating medium was replaced by serum-free culture medium (SFM-PBCEC) (Dulbecco’s modified Eagle’s medium/Ham’s F 12 (1:1) containing 4.1 mM L-glutamine, 100 µg/mL gentamycin, 100 U/mL penicillin, 100 µg/mL streptomycin (all Biochrom, Berlin, Germany)) and 550 nM hydrocortisone (Sigma-Aldrich, Deisenhofen, Germany) in order to induce differentiation. Permeability (¹⁴C-sucrose, MnCl₂) and barrier integrity studies were started on day DIV6.

**BBB co-culture model** – A co-culture model of PBCECs and CCF-STTG1 was used as described previously (23). CCF-STTG1 (CCL-1718™, American Type Culture Collection, Bethesda, MD, USA) cells were cultured in RPMI 1640 (Biochrom, Berlin, Germany) containing 10% fetal bovine serum (PAA Laboratories, Pasching, Austria), 1.4 mM L-glutamine (Biochrom, Berlin, Germany), 100 U penicillin/mL and 100 µg streptomycin/mL (PAA Laboratories, Pasching, Austria) at 37°C with 5% CO₂ and 100% humidity. For the co-culture system, CCF-STTG1 cells were trypsinized and seeded (100,000 cells/cm²) on the lower side of the microporous Transwell® filter insert (Corning, Wiesbaden, Germany, 1.12 cm² growth area, 3 µm pore size) in order to simulate a direct co-culture. Six hours later, the inserts were turned round, placed into the well and PBCECs were seeded on the upper side of the insert, which was coated with rat tail collagen and the co-culture system was subsequently cultured as described above.

**Blood-CSF barrier cell culture model** – PCPECs were seeded on matrigel-coated (Sigma-Aldrich, Deisenhofen, Germany) microporous Transwell® filter inserts in the apical compartment using a seeding density of 30 cm⁻²/g wet weight of choroid plexus tissue (DIV1). Thereafter, medium was changed every second day. On day DIV8, cells reached confluence and the medium was replaced by serum-free medium (SFM-PCPEC) (Dulbecco’s modified Eagle’s medium/Ham’s F 12 (1:1) supplemented with 4 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 5 µg/mL insulin) to allow full cell differentiation. The cells were further supplemented with SFM on DIV11 and barrier integrity and transport studies were started on day DIV13, when the cells were fully differentiated and built up their respective functions (21,24). PCPECs started to actively pump medium from the basolateral into the apical chamber, a process, which is comparable to the secretion of cerebrospinal fluid in vivo, and transported phenol red to the basolateral chamber. Additionally, the transepithelial electrical resistance (TEER₆) increased.

**TEER and capacitance measurements** – The transendothelial electrical resistance (TEER₈) and the transepithelial electrical resistance (TEER₆) were used as parameters for integrity of the respective barriers, measured by the cellZscope® (nanoAnalytics, Münster, Germany) device. The module used was suitable for 24 Transwell® filter system, grown with PBEC or PCPEC monolayer. The determined capacitance is directly proportional to the plasma membrane surface area. Changes in the basolateral area and changes in protein content and distribution may also contribute to capacitance changes. Only wells with TEER₈ values > 600 Ω x cm² and capacitance values between 0.45 and 0.6 µF/cm² on day DIV6 indicate a confluent PBEC monolayer with good barrier properties and were used for the respective experiments. On day DIV13, wells with PCPEC monolayer in which the TEER₈ values dropped below 600 Ω x cm² and/or capacitance values dropped below 3.3 µF/cm² were excluded from the respective experiment.

**¹⁴C-sucrose permeability** – Another technique to analyze barrier integrity is the determination of the permeability for radiolabeled ¹⁴C-sucrose through the endothelial or epithelial cell layer. Since sucrose is not taken up by endothelial and epithelial cells either by active or facilitated transport, the permeability for sucrose solely depends on the paracellular barrier tightness. At defined time points, as indicated in the respective experiments, radiolabeled ¹⁴C-sucrose (Amersham, Buckinghamshire, UK) was added to the apical side of the Transwell® filter. By measuring the time-dependent amount of ¹⁴C-sucrose which passes to the basolateral side, the permeability was calculated as described previously (22).

**Mn induced effects on and transfer over the barrier models** – To study the impact of Mn on the barrier integrity as well as Mn transfer across the accomplished in vitro barriers, the respective in vitro models were exposed to MnCl₂ either on the apical or on the basolateral side or on both sides simultaneously. MnCl₂ was applied by replacing 10% of the apical and/or basolateral medium by a freshly prepared MnCl₂ solution to finally reach concentrations of 1 – 500 µM MnCl₂ as described in...
the respective experiments. During the following 72 h of incubation, aliquots were sampled from the apical and basolateral compartments for the FIA-ICP-QMS measurements while online monitoring the respective TEER N/P and capacitance values. Finally, Mn transfer from one to the other compartment was expressed in % (in relation to the applied concentration), as concentration (in mM) in each of the compartments as well as in case a time-dependent linear correlation as permeability coefficients in cm/sec (25). Regarding blood-CSF barrier, function of the barrier was additionally assessed by determination of the absorbance (558 nm, NanDrop 1000, PEQLAB Biotechnologie GMBH, Erlangen, Germany) of phenol red in the respective compartments.

In a further, preliminary experiment the DMT1 inhibitor NSC306711 was used to assess the role of DMT1 in the Mn transfer across the blood-CSF barrier. Therefore, the inhibitor stock solutions were prepared in DMSO and the basolateral compartments of the blood-CSF in vitro barrier model were incubated with 5, 10, 50 and 100 µM NSC306711 (with a final DMSO concentration ≤1%) immediately prior to the basolateral incubation with MnCl2 (10, 25 µM). Additionally, basolateral incubation with 1% DMSO was carried out as vehicle control.

The role of the Na⁺,K⁺-ATPase in Mn transfer was examined incubating 200 nM of the selective Na⁺,K⁺-ATPase inhibitor ouabain in the basolateral compartment of the blood-CSF in vitro barrier model immediately prior to the basolateral or apical incubation with 10 µM MnCl₂.

To study the impact of Ca-enriched media on Mn induced disturbance of blood-CSF barrier properties, Transwell® filters with PCPEC monolayers were preincubated with 200 µM MnCl₂ at the basolateral compartment for 24 h. Thereafter, the respective basolateral media were kept for further 72 h or replaced by either fresh SFM or by fresh SFM enriched with 250 or 500 µM CaCl₂ and postincubated for 72 h.

**Immunocytochemistry** – Immunocytochemistry studies were performed with PCPEC monolayers grown on the Transwell® filters as described previously (26,27). 1 µg/ml mouse anti-occludin (Zytomed, Berlin, Germany) and 5 µg/mL mouse anti-Na⁺,K⁺-ATPase (Upstate Biotech, NY) were applied at 37°C in a 0.5 % BSA (Roth, Karlsruhe, Germany) solution for 30 and 90 min, respectively.

The secondary antibody alexa fluor® 546 goat anti-mouse (1 µg/mL) (Invitrogen, Paisley, UK) was also diluted in 0.5 % BSA and incubated for 1 h at 37°C. Additionally, cell nuclei were stained with 10 µg/ml Hoechst 33258 (Bisbenzimide,Sigma-Aldrich, Deisenhofen, Germany) for 0.5 min. Filters with immunostained cells were cut out from the inserts, and mounted in Aqua Poly/Mount (Polysciences,Washington, USA). Pictures were taken with the fluorescence microscope Axio ImagerM2 (Zeiss, Oberkochen, Germany) and evaluated with Axiovision 4.5 software (Zeiss, Göttingen, Germany).

**Cytotoxicity testing of MnCl₂** – Cytotoxic effects of MnCl₂ on PBCECs and PCPECs were evaluated using the neutral red uptake assay. This assay is based on the ability of viable cells to incorporate and bind the supravital dye neutral red in the lysosomes (28). PBCECs and PCPECs were cultured in 96-well culture plates, which in case of PBCECs were coated with rat tail collagen. Thereby, all culture conditions including media and cell density were absolutely analogous to the below mentioned cultivation of the respective cells on Transwell® filters as well as to the cellular bioavailability studies. Incubation of PBCECs and PCPECs with MnCl₂ was performed on day in vitro 6 (DIV6) and DIV13, respectively. After 24 or 72 h incubation, the medium was replaced by neutral red (3-amino-7-dimethylamino-2-methylphenazine hydrochloride) containing medium (70 mg/L neutral red (Sigma-Aldrich, Deisenhofen, Germany) in serum-free medium used for the respective cells). After dye loading (37°C, 3 h), cells were washed with phosphate buffered saline (PBS) containing 0.5 % formaldehyde (Roth, Karlsruhe, Germany), the incorporated dye was solubilised in 100 µL acidified ethanol solution (50 % ethanol, 1 % acetic acid in PBS) and finally the absorbance in each well was measured by a plate reader (FLUOstar Optima, BMG Labtechnologies, Jena, Germany) at 540 nm.

**Mn quantification in cells and media** – Cellular Mn content was determined afterashing of cells by inductively coupled plasma mass spectrometry (ICP-MS). Due to the low number of cells used and the low Mn concentrations applied in the barrier studies, we were not able to quantify the total Mn content in cells grown on Transwell® filters, but had to use cells, which were grown in culture flasks. Briefly, after 48 h incubation with MnCl₂ PBCECs grown on rat tail collagen-coated culture flasks (25 cm²) or PCPECs grown on culture flasks (25 cm²) were washed twice with PBS (37°C) and incubated 15 min on ice with 300 µL RIPA-buffer (0.01 M Tris (pH 7.6), 0.15 M NaCl, 0.001 M EDTA, 0.001 M PMSF, 1% sodium deoxycholate, 1mg/mL aprotinin, 1µg/mL leupeptin, 1µg/mL, pepstatin, 0.1% SDS (all Sigma-Aldrich, Deisenhofen, Germany)). Cells were scrapped off, sonicated on ice, the cell suspension was centrifuged at 15.000 x
RESULTS

Cytotoxicity testing – In PCPECs, Mn showed no cytotoxicity as measured by the neutral red uptake assay after 24 and 72 h incubation with up to 1000 µM MnCl₂ (fig. 1). In contrast, in PBCECs cellular viability declined in a concentration and time dependent manner. The online measurement of the electrical capacitance further confirmed cytotoxicity of MnCl₂ in PBCECs by a concentration dependent increase (data not shown).

Mn bioavailability – The applied culture media contained 0.03 µM ± 0.01 µM Mn, which is comparable to the reported normal Mn contents in human serum (30). Total Mn concentrations in non-exposed cells were comparable in both cell types, whereas after 48 h MnCl₂ incubation, cellular total Mn concentration was about three fold lower in PBCECs as compared to PCPECs (table 2). Thus, very interestingly, even though showing lower cellular Mn bioavailability, PBCECs are more sensitive towards Mn cytotoxicity as compared to PCPECs.

MnCl₂ and the BBB – In the first set of experiments, a well characterised cell culture model of the BBB consisting of PBCECs (19,22) was incubated with increasing concentrations of MnCl₂. The PBCECs were grown on Transwell® filter inserts, thereby building up a two chamber system, which mimics the in vivo CNS situation as closely as possible. The apical compartment refers to the blood side in vivo and the basolateral side refers to the brain side. The impact of MnCl₂ on the barrier integrity was quantified monitoring the TEERₙ values during the entire 72 h of Mn incubation.

Incubating MnCl₂ on the apical side, impedance analysis (fig. 2a) indicated no measurable effect on barrier integrity up to an incubation concentration of 100 µM MnCl₂. MnCl₂ concentrations of 150 and 175 µM strongly decreased TEERₙ values within the first 12 hours of incubation, but allowed a reconstitution of the barrier integrity in the following hours. In contrast, 200 µM MnCl₂ caused an irreversible decrease of the TEERₙ, indicating an irreversible disruption of the BBB. To verify the results of the TEERₙ studies, barrier integrity was additionally determined by ⁴¹C-sucrose permeability studies. In case of an apical 72 h incubation with 200 or 300 µM MnCl₂, the permeation of ⁴¹C-sucrose was about 8 to 100fold increased as compared to control cells (fig. 2c), indicating strong barrier leakage and disruption. In case of an incubation on the basolateral side, the tightness of the PBCEC monolayer was not impaired by up to 500 µM MnCl₂ (fig. 2b); similarly permeability for ⁴¹C-sucrose was not affected (fig. 2e).

For better understanding, Mn barrier transfer results are shown in the respective figures expressed in terms of Mn concentrations in the acceptor compartment (fig. 2c), as percental permeability in relation to the applied concentration (fig. 2d) and as permeability coefficient (fig. 2e). In case of adding ≤ 100 µM MnCl₂ to the apical compartment, after 24 to 72 h Mn concentrations increased in a linear dependent manner in the basolateral compartment (fig. 2e). Figure 2d shows the corresponding crossover of about 15 % within 24 h and about 30 % within 72 h, which relates to a permeability coefficient of 1.40*10⁻⁵ ± 1.07*10⁻⁷ cm/s (fig. 2e).

Due to the leakage of the barrier after incubation with MnCl₂ concentrations >100 µM on the apical side (fig. 2a), a Mn concentration equation between the compartments (fig. 2d) and thus increased permeability coefficients of up to 3.52*10⁻⁶ ± 3.45*10⁻⁷ (300 µM MnCl₂) (fig. 2e) were achieved. Since in literature very little is known about Mn movement out of the brain into the blood MnCl₂ was
added to the basolateral side in a second approach. Our data clearly show that up to MnCl₂ concentrations of 50 µM, Mn basolateral-to-apical transfer was indistinguishable from the apical-to-basolateral transfer. This indicates that after incubation on the basolateral or the apical side, Mn crossed the barrier in both directions (apical-to-basolateral and basolateral-to-apical transfer) in a comparable extent. In case of basolateral incubation with concentrations > 50 µM MnCl₂, respective percental Mn permeabilities (fig. 2d) and permeability coefficients (fig. 2e) were strongly reduced.

In a third approach, MnCl₂ was incubated in equal concentrations both to the apical and the basolateral medium. No accumulation was visible in one of the compartments within 72 h of incubation with 50 µM MnCl₂, pointing to a passive Mn transfer process (fig. 2f). The TEERₐ analyses showed similar results as compared to a MnCl₂ incubation on the apical side and thereby also ruled out that the observed effects on the TEERₐ values in general were caused by an ionic effect of Mn²⁺.

In addition to the monoculture BBB experiments, a direct co-culture approach (23) based on the BBB architecture in vitro was used, in which brain capillaries are entirely covered by astrocytic feed. After apical MnCl₂ incubation, neither the TEERₐ analyses nor the transfer experiments showed significant different results as compared to the monoculture studies (data not shown).

MnCl₂ and the blood-CSF barrier – The next set of experiments focused on the second cellular interface, which regulates the exchange between the blood and CNS, the blood-CSF barrier. The applied, well established in vitro cell culture model of the blood-CSF barrier is built up by PCPECs (20), shows several features of physiological activity and mimics the in vivo situation quite closely (21,24). In this in vitro model, the apical side of the PCPEC layer mimics the ventricular compartment, whereas the basolateral side represents the blood side in vivo. For the characterization of the structural and functional properties of the in vitro blood-CSF barrier, different parameters were used. The transepithelial electrical resistance (TEERₐ) and 14C-sucrose permeability were determined to characterize barrier tightness. Functional changes could be shown by the capacitance, the active fluid secretion and the phenol red concentration in the upper (apical) chamber. While the in vitro barrier was not affected after basolateral incubation with up to 25 µM MnCl₂, tightness and function of the PCPEC monolayer were concentration-dependently disturbed after basolateral incubation with ≥ 50 µM MnCl₂. Thus TEERₐ and capacitance values decreased (fig. 3a, b), pointing to a barrier disruption and a decreased number of PCPECs microvilli, respectively. Moreover, fluid secretion was reduced (data not shown) and phenol red concentration increased on the apical side (fig. 3c), indicating an adverse effect on the proper function of the organic anion transporter, which is driven by the Na⁺,K⁺-ATPase. Barrier leakage was additionally confirmed by the results of the 14C-sucrose permeability studies (fig. 4c).

Similarly to the BBB in vitro model, in the blood-CSF barrier model Mn affected barrier integrity stronger after incubation on the blood side. After apical exposure, an impairment of the barrier tightness (fig 3d) and function (data not shown) was not visible until 200 µM MnCl₂.

The time profiles of the basolateral-to-apical Mn transfer (fig. 4a) and apical-to-basolateral Mn transfer (fig. 4b) clearly demonstrate a higher transfer rate from basolateral incubated Mn into the apical compartment as compared to the other direction. In case of basolateral incubation with ≤ 50 µM MnCl₂, after 48 h of incubation Mn accumulated in the brain facing compartment, whereas after barrier disruption by 200 µM MnCl₂, a concentration equation was achieved between the compartments (fig. 4a). Because of the missing linear correlation, the basolateral-to-apical Mn transfer could not be expressed as permeability coefficient. Very interestingly, only about 20 % of the apical dose applied (50, 200 µM MnCl₂) reached the basolateral compartment (fig. 4b) corresponding to permeability coefficients of around 1*10⁻⁶ cm/s (fig. 4c). Further studies, applying an equal MnCl₂ concentration (10 µM) in each compartment, demonstrate a Mn accumulation in the apical compartment (fig. 4d). This clearly points to an active transport mechanism. In case of a parallel incubation with 200 µM MnCl₂ due to a barrier disruption, a concentration equation was achieved between the compartments (fig. 4d).

In order to identify possible transport mechanisms for Mn cellular uptake, the well characterised DMT1 inhibitor NSC306711 (31), incubated immediately prior MnCl₂ (10, 25 µM) at the basolateral compartment, was used. Considering experiments with fully intact barriers in the presence of ≤ 50 µM NSC306711, Mn basolateral-to-apical transfer was not significantly different as compared to the studies without the inhibitor (data not shown).

Effect of Ca on the Mn-induced blood-CSF barrier disturbance – Further studies determining the impact of calcium (Ca) on Mn induced disturbance of blood-CSF barrier properties refer to a reconstitution of barrier properties by Ca postincubation. Thus, filters of the in vitro blood-
CSF barrier model were treated with 200 µM MnCl₂ at the basolateral compartment in order to strongly disturb barrier integrity and function. After 24 h of MnCl₂ incubation, the basolateral medium was replaced with SFM (containing about 1000 µM Ca) or CaCl₂ enriched medium (SFM + 250 or 500 µM Ca). In case of a postincubation with SFM or Ca enriched SFM, a reconstitution of the barrier tightness was clearly visible as measured by an increase of the respective TEERₚ values (fig. 5a). Moreover, capacitance values, active fluid secretion to the apical compartment and transport of phenol red to the basolateral compartment increased again (data not shown). Concordantly, the ¹⁴C-sucrose permeability studies revealed the restored barrier tightness after Ca postincubation (fig. 5b). As expected, the replacement of the basolateral medium did not result in a reduction of the apical manganese concentration (data not shown).

The barrier properties of the epithelial cell monolayer were further investigated by the immunocytochemical analysis of occludin, a protein that is a central functional component of tight junctions (32). In non-exposed PCPECs, occludin staining appeared (33) in clear lines, without any fuzzy appearance, and cell borders were mostly straight and not serrated (fig. 5c [I]). In contrast, filters treated for 24 h with 200 µM MnCl₂ (fig. 5c [II]) showed more serrated and perforated cell borders, indicating that tight junctions were not fully closed anymore. Apparently, the subsequent replacement of the basolateral MnCl₂ incubated medium with Ca-enriched SFM resulted in a relock of the tight junctions, leaving only a few areas with not fully closed tight junctions (fig. 5c [III]). Comparable studies using the in vitro BBB model, in which 200 µM MnCl₂ were preincubated to the apical compartment for 24 h and then postincubated with SFM or Ca-enriched SFM demonstrate no reversibility of the manganese induced effects in this model (data not shown).

Mn and the Na⁺,K⁺-ATPase in the blood-CSF barrier

The role of Na⁺,K⁺-ATPase in Mn transfer was studied via a basolateral incubation with its selective inhibitor ouabain immediately prior apical or basolateral incubation with 10 µM MnCl₂. Within the following 72 h neither the basolateral-to-apical nor the apical-to-basolateral transfer was significantly different from the studies in the absence of ouabain (fig. 6a). At the same time Na⁺-K⁺-ATPase activity was clearly affected, as measured by an increase of the phenol red concentration on the apical side.

Immunological Na⁺-K⁺-ATPase staining reveals that in non-exposed as well as ouabain treated (24 – 72 h) cells Na⁺,K⁺-ATPase is located at the luminal surface (fig. 6b [I],[II]). In contrast, filters which were treated for 24 h with 200 µM MnCl₂ in the basolateral compartment had a significantly reduced Na⁺,K⁺-ATPase signal (fig. 6b [III]); a 72 h incubation with MnCl₂ showed similar effects (data not shown). After an additional 48 h postincubation with CaCl₂, Na⁺,K⁺-ATPase is located again at the luminal surface (fig. 6b [IV]).

DISCUSSION

A crucial poorly understood step in Mn induced neurotoxicity is its effect on and its transfer across the two brain regulating interfaces, the BBB and the blood-CSF barrier. In the present study, well established porcine based cell culture models were used, with PBCECs and PCPECs as structural basis of the BBB and the blood-CSF barrier, respectively. It is well known that pig brain shows more similarities to human brain, with respect to size, anatomy growth and development, as compared to brains of other laboratory animals including rodents. This makes porcine in vitro systems important experimental models to be considered within neurosciences (34-36). Additionally, these primary cultures obtained from freshly slaughtered pigs have the clear advantage of being an alternative approach to the costly, time-consuming and ethically questionable systems derived from experimental animals.

Regarding the in vitro BBB studies in the present work, the data clearly show that barrier leakage caused by ≥ 200 µM MnCl₂ in the apical, blood resembling compartment correlated with Mn cytotoxicity. Results obtained from TEERₚ measurements were confirmed by ¹⁴C-sucrose permeability studies, which similarly indicated an alteration of paracellular tightness in the presence of elevated Mn concentrations. In contrast, a basolateral MnCl₂ incubation, which simulates an in vivo situation after Mn accumulation in specific brain regions (37), did not affect barrier integrity up to 500 µM MnCl₂, a concentration clearly being not exposure relevant anymore. In brain tissues, physiological Mn concentrations range from 2 to 8 µM, but can be increased several fold upon overexposure (38,39). Together with the observed small Mn efflux in case of high Mn concentrations (≥ 100 µM) to the basolateral compartment (blood side), these results are in agreement with in vivo studies, in which Mn after entering the brain, strongly persists and therefore accumulates in the brain (40,41). Evidence suggests that brain Mn efflux across the BBB proceeds through slow diffusion (42), which is supported by our data. In case of lower applied MnCl₂ concentrations (≤ 50
μM), comparable apical-to-basolateral (influx) and basolateral-to-apical (efflux) transfer rates after incubation in one of the respective compartments as well as the missing Mn accumulation in one compartment after parallel incubation on both, apical and basolateral, sides, strongly point to a passive transfer process of Mn across the BBB. The influx permeability coefficient across the BBB for divalent Mn is for example comparable to the influx permeability coefficient of morphine in the same in vitro model (25).

One very important outcome of the present work is the fact that in direct comparison to the in vitro BBB model, the blood-CSF barrier model was much more sensitive towards Mn. The disturbance of barrier properties was not caused by Mn cytotoxicity. The observed higher cytotoxic resistance and Mn bioavailability in PCPECs as compared to PBCECs suggests a several orders of magnitude higher Mn uptake and accumulation by the CP in comparison to other brain regions (43).

Similar to the BBB model, blood-CSF barrier properties were most strongly affected after MnCl2 incubation on the blood side, which is in blood-CSF barrier model the basolateral compartment. Thus, barrier tightness and functions were strongly disturbed after basolateral incubation with ≥ 50 μM MnCl2 and apical incubation with ≥ 200 μM MnCl2, respectively. Moreover, apical-to-basolateral Mn transfer was much lower as compared to basolateral-to-apical transfer, which has very recently also been reported in a rat based blood-CSF barrier model (44).

The observed Mn induced decrease of active fluid secretion and phenol red transport might be due to an inhibition of Na⁺,K⁺-ATPase function by Mn. In the CP epithelium, the Na⁺,K⁺-ATPase is the driving force of the active fluid secretion and is furthermore a major player of various active transport properties including transport of phenol red from apical to basolateral compartment. Disturbance of Na⁺,K⁺-ATPase function might result from an inhibition of the Na⁺,K⁺-ATPase activity, which has been described in neuroblastoma cells or liver tissue by Mn before (45,46), but might also be due to Na⁺,K⁺-ATPase internalization following a phosphorylation of a Na⁺,K⁺-ATPase subunit. The immunocytochemistry studies carried out in this work strongly argue for such a Na⁺,K⁺-ATPase internalization in the presence of high MnCl2 concentrations. Na⁺,K⁺-ATPase has also been reported to be inhibited by ROS in primary cultures (47) and it is generally known that Mn overexposure induces a transient increase in the cellular ROS level of brain cells (48,49).

Additionally, chronic Mn exposure might alter systematic homeostasis of calcium, leading to a further impairment of Na⁺,K⁺-ATPase function (14,50). As further barrier integrity disturbing mechanism, occludin immunocytochemistry studies reveal a disturbance of tight junction structure, which might also be partly caused by an inhibition of Na⁺,K⁺-ATPase function (51).

Regarding the type of Mn influx via the blood-CSF barrier, our data argue for an active transport mechanism. As summarized in (44), many transporters are expressed in the CP and are therefore discussed to contribute to Mn transport. Since DMT1 has been shown to be present in the blood-CSF barrier in several studies and Mn exposure resulted in an increased DMT1 expression in rats (52), the present study intended to assess the role of DMT1 in Mn transfer processes. However, applying the DMT1 inhibitor NSC 306711, our data show that in the applied in vitro system DMT1 is not the major transporter for Mn uptake into the brain via the blood-CSF barrier. This data account with studies in which Mn uptake was not significantly reduced in homozygous Belgrade rat (b/b) with no functional DMT1-expression (53). The application of the selective Na⁺,K⁺-ATPase inhibitor ouabain did not result in a decrease of Mn transfer across the blood-CSF barrier, indicating that Mn transfer is independent of Na⁺,K⁺-ATPase function, which has been published by Crossgrove et al. (2005) before (54). In contrast, recent evidence has clearly shown that in a rat model upon Mn treatment, MTP1 (also named ferroportin 1) is visibly translocated from the diffuse distribution in the cytosol to apical microvilli of the CP and transports excess amounts of intracellular Mn towards the CSF. Furthermore, it is interesting to note that similar to MTP1, the direction of cellular TRP trafficking was also towards the CSF (55).

Mn uptake in the CP has been reported to be stronger than in other brain regions, whereas Mn concentrations in CSF are comparably low, indicating no strong Mn efflux from CP into CSF. Thus, physiological Mn concentrations in CSF are comparable to serum concentrations, ranging from 1.0 ± 0.5 μg/L in non-exposed patients to several fold higher levels in exposed patients (56,57). This fact might have contributed to the assumption frequently discussed in literature that Mn enters the brain at normal physiological plasma concentrations across the capillary endothelium, whereas at high plasma concentrations, Mn transfer across the choroid plexus appears to predominate (3,43).

However, taking into account the data in this work, in which for the first time Mn transfer across
the two barriers has been compared in one study, this assumption has to be critically assessed.
Moreover, in the present study we showed for the first time that a basolateral postincubation with Ca can compensate for Mn induced disturbance of blood-CSF barrier properties, restoring both barrier tightness and function. Intracellular Ca homeostasis has a strong impact on tight junction integrity and a decrease in intracellular Ca levels has been shown to alter subcellular localization of occludin and changes Zo-1/actin binding (58). In biological systems, Mn$^{2+}$ has the same charge and relative size as Ca$^{2+}$ and a number of reports have shown that Mn and Ca trafficking, recruitment and storage are regulated by the same ion pumps and intracellular compartments. Therefore, Mn$^{2+}$ might compete with Ca$^{2+}$ in uptake studies (59,60), thereby disturb intracellular Ca homeostasis and correct tight junction formation and/or localisation (26,61). This effect might be reversible by elevated Ca concentrations, as indicated by the present occludin immunofluorescence studies. Moreover, a recovery of Na$^+$/K$^+$-ATPase function, which is also coupled to intracellular Ca homeostasis, might also contribute to the observed Ca-mediated reversibility of Mn-induced barrier disturbance. Further studies should examine these interactions in more detail, which might also help to understand the mechanism of Mn induced barrier disruption.

CONCLUSION

By the use of state-of-the in vitro barrier models effects of Mn on the integrity of the blood-brain and blood-CSF barrier as well as Mn transfer across these two barriers in both directions were compared in one study for the first time. In summary, both the observed stronger Mn sensitivity of the in vitro blood-CSF barrier and the observed site directed, most probably active Mn transport towards the brain facing compartment, reveal that, in contrast to the general assumption in literature, the blood-CSF barrier might be the major route for Mn into the brain after oral Mn intake.
REFERENCES

**Acknowledgements** - We thank the Developmental Therapeutics Program of the National Cancer Institute for procuring the test substance NSC 306711 used in this study. We also appreciate Dr. Aaron Bowman for helpful discussions regarding the NSC 306711 studies. This work was supported by the Graduate School of Chemistry (WWU Münster, Germany)
FIGURE LEGENDS

Figure 1. Cytotoxicity of MnCl₂ in confluent PBCECs and PCPECs after 24 h or 72 h incubation. Cytotoxicity was determined by a decrease in the cell viability as determined by the neutral red uptake assay. The data represent mean values of at least 3 independent determinations with 6 replicates each ± SD.

Figure 2. Mn and the *in vitro* blood-brain barrier. Impact of MnCl₂ on the barrier integrity as measured by TEERₐ values after application of MnCl₂ either on the apical (influx studies) [A] or the basolateral compartment (efflux studies) [B]. Data, expressed as % of start value, represent mean values of at least 3 independent determinations with each 3 replicates with SD < ± 10 %. Mean TEERₐ and capacitance values of control cells were 1016 ± 124 Ω * cm² and 5.19 * 10⁷ ± 2.55 * 10⁸ µF/cm², respectively. Concentration-dependent Mn transfer to the respective acceptor (not incubated) compartment [C], percental, normalized to the incubation concentration, Mn transfer [D] after apical or basolateral MnCl₂ incubation. Mn permeability coefficients and respective permeability coefficients of the permeability marker ¹⁴C-sucrose after 72 h MnCl₂ apical or basolateral incubation [E]. Mn permeability after concurrent MnCl₂ incubation of both compartments [F]. [C-F] Shown are mean values of least 3 independent determinations with 3 replicates ± SD. (a → b) = apical-to-basolateral transfer; (b → a) = basolateral-to-apical transfer

Figure 3. Mn and the *in vitro* blood-CSF-barrier. Impact of MnCl₂ on the barrier integrity (TEERP) [A] and the capacitance [B] after basolateral MnCl₂ incubation. Data, expressed as % of start value, represent mean values of at least 3 independent determinations with each 3 replicates with SD < ± 10 %. Mean TEERP and capacitance values of control cells were 801 ± 96 Ω * cm² and 3.75 * 10⁻⁶ ± 2.09 * 10⁻⁷ µF/cm², respectively. [C] Phenol red concentration measured at 558 nm after 72 h basolateral MnCl₂ incubation. Shown are mean values of at least 3 independent determinations with 3 replicates ± SD. [D] Influence of MnCl₂ on the TEERP values after apical MnCl₂ incubation. Data, expressed as % of start value, represent mean values of at least 3 independent determinations with 3 replicates with SD < ± 10 %.

Figure 4. Mn transfer across the *in vitro* blood-CSF-barrier. Mn transfer after MnCl₂ incubation of the basolateral compartment (influx studies) [A] or the apical compartment (efflux studies) [B]. Data are expressed as % of the respective incubated MnCl₂ concentration; open symbols represent quantified Mn concentrations in the apical, closed symbols in the basolateral compartment. [C] Mn permeability coefficients and respective permeability coefficients of the permeability marker ¹⁴C-sucrose after 72 h MnCl₂ basolateral or apical incubation. Due to missing linearity basolateral-to-apical, Mn permeability coefficient cannot be calculated. [D] Mn permeability after concurrent MnCl₂ incubation of both compartments. [A-D] Data represent mean values of at least 3 independent determinations with each 3 replicates ± SD. a = apical compartment; b = basolateral compartment; (a → b) = apical-to-basolateral transfer; (b → a) = basolateral-to-apical transfer

Figure 5. Effect of Ca on the Mn-induced blood-CSF barrier disturbance. Relative TEERP values [A] and respective ¹⁴C-sucrose permeability coefficients [B] after 24 h preincubation with 200 µM MnCl₂, medium exchange at the basolateral compartment and postincubation without/with Ca-enriched medium (Ca-concentration in medium of the choroid plexus epithelial cells: 1013 µM). Shown are data from one representative experiment (n = 3 with SD < ± 10 %). [C] Immunocytochemical staining of occludin. Shown are representative images for [I] non-treated (TEERP = 802 Ω*cm²) barriers, [II] barriers after basolateral incubation with 200 µM MnCl₂ for 24 h (TEERP = 120 Ω*cm²) and [III] barriers after 24 h basolateral preincubation with MnCl₂ and 48 h postincubation with Ca-enriched SFM (SFM + 250 µM CaCl₂ (TEERP = 681 Ω*cm²).

Figure 6. Mn transfer across the *in vitro* blood-CSF-barrier without/with the Na⁺,K⁺-ATPase-inhibitor ouabain (200 nM) [A]. Shown are mean values of 3 determinations ± SD. Immunocytochemical staining of the Na⁺,K⁺-ATPase [B]. Shown are representative images for [I] non-treated (TEERP = 822 Ω*cm²) barriers, [II] barriers after basolateral incubation with 200 nM ouabain for 72 h (TEERP = 868 Ω*cm²), [III] barriers after basolateral incubation with 200 µM MnCl₂ for 24 h (TEERP = 110 Ω*cm²) and [IV] barriers after 24 h basolateral preincubation with MnCl₂ and 48 h postincubation with Ca-enriched SFM (SFM + 250 µM CaCl₂ (TEERP = 720 Ω*cm²). (a → b) = apical-to-basolateral transfer; (b → a) = basolateral-to-apical transfer.
### TABLE 1. ICP-QMS parameters used for FIA measurements.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Power</td>
<td>1550 W</td>
</tr>
<tr>
<td>Cool gas flow</td>
<td>14 L/min</td>
</tr>
<tr>
<td>Auxiliary gas flow</td>
<td>0.8 L/min</td>
</tr>
<tr>
<td>Nebulizer gas flow</td>
<td>≈ 1 L/min</td>
</tr>
<tr>
<td>Nebulizer type</td>
<td>µFlow PFA-ST (ESI, Omaha, NE, USA)</td>
</tr>
<tr>
<td>Injector inner diameter (ID)</td>
<td>1.8 mm</td>
</tr>
<tr>
<td>Spray chamber type</td>
<td>Cyclone @ 2.7 °C</td>
</tr>
<tr>
<td>Mode</td>
<td>CCTED</td>
</tr>
<tr>
<td>Cell gas</td>
<td>7% H₂ in He (purity &gt; 99.999%)</td>
</tr>
<tr>
<td>Cell gas flow</td>
<td>≈ 5 mL/min</td>
</tr>
<tr>
<td>Δbias</td>
<td>3 V</td>
</tr>
<tr>
<td>Dwell time</td>
<td>50 ms @ 1 channel</td>
</tr>
</tbody>
</table>

### TABLE 2. Cellular bioavailability of MnCl₂ in PBCECs and PCPECs after 48 h incubation. Data represent mean values of at least 2 independent determinations with each 2 replicates ± SD.

<table>
<thead>
<tr>
<th>Incubated MnCl₂ [µM]</th>
<th>Cellular Mn in PBCECs [µg Mn/mg protein]</th>
<th>Cellular Mn in PCPECs [µg Mn/mg protein]</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.20 ± 0.03</td>
<td>0.20 ± 0.01</td>
</tr>
<tr>
<td>50</td>
<td>1.14 ± 0.18</td>
<td>3.33 ± 0.05</td>
</tr>
<tr>
<td>200</td>
<td>2.90 ± 0.76</td>
<td>7.63 ± 1.76</td>
</tr>
</tbody>
</table>
Fig. 1

![Graph showing the effect of MnCl$_2$ concentration on viability of cells]

- **Viability [% of control]**
- **MnCl$_2$ [µM]**

Legend:
- 24 h PCPEC
- 72 h PCPEC
- 24 h PBCEC
- 72 h PBCEC
Fig. 2

A

Fig. 2A: Graph showing TEER (% of start value) over time with different concentrations of MnCl$_2$.

B

Fig. 2B: Graph showing TEER (% of start value) over time with different concentrations of MnCl$_2$.

C

Fig. 2C: Graph showing Mn in the respective acceptor compartment [µM] with different concentrations of MnCl$_2$.

D

Fig. 2D: Bar graph showing permeability [%] with different concentrations of MnCl$_2$.

E

Fig. 2E: Graph showing permeability [cm/sec] with different concentrations of MnCl$_2$.

F

Fig. 2F: Graph showing permeability [%] with different concentrations of MnCl$_2$.
Fig. 3

A

TEERp [% of start value]

Time [h]

0 µM 1 µM 50 µM 10 µM 25 µM 100 µM 200 µM

B

Capacitance [% of control]

Time [h]

0 µM 1 µM 50 µM 10 µM 25 µM 100 µM 200 µM

C

Absorption [558 nm]

MnCl₂ [µM]

apical compartment
basolateral compartment

D

TEEP [% of start value]

Time [h]

0 µM 50 µM 100 µM 150 µM 200 µM

MnCl₂
Fig. 4

A  
![Graph A](MnCl2)  
\[a \rightarrow b \ (\text{MnCl}_2)\]

B  
![Graph B](MnCl2)  
\[a \rightarrow b \ (\text{MnCl}_2)\]

C  
![Graph C](MnCl2)  
\[a \rightarrow b \ (\text{MnCl}_2)\]

D  
![Graph D](MnCl2)  
\[a \rightarrow b \ (\text{MnCl}_2)\]
Fig. 5

A

![Graph showing TEER over time with various treatments.](image)

B

![Bar graph showing 14C-sucrose permeability with different treatments.](image)

C

![Images illustrating different MnCl₂ treatments.](image)

[1] 0 µM MnCl₂

TEER₀ = 802 Ω·cm²

[II] 200 µM MnCl₂ (24 h)

TEER₀ = 120 Ω·cm²

[III] 200 µM MnCl₂ (24 h); CaCl₂ (48 h)

TEER₀ = 681 Ω·cm²
Fig. 6

A

![Bar graph showing permeability over time with different treatments](image)

- **10 µM MnCl<sub>2</sub>**
- **ouabain + 10 µM MnCl<sub>2</sub>**

B

[I] 0 µM MnCl<sub>2</sub>

TEER<sub>a</sub> = 822 Ω·cm<sup>2</sup>

[II] 200 nM Ouabain (72 h)

TEER<sub>b</sub> = 868 Ω·cm<sup>2</sup>

[III] 200 µM MnCl<sub>2</sub> (24 h)

TEER<sub>0</sub> = 110 Ω·cm<sup>2</sup>

[IV] 200 µM MnCl<sub>2</sub> (24 h);

CaCl<sub>2</sub> (48 h)

TEER<sub>b</sub> = 720 Ω·cm<sup>2</sup>
Impact of manganese on and transfer across the blood-brain and blood-CSF barrier in vitro
Julia Bornhorst, Christoph A. Wehe, Sabine Huwel, Uwe Karst, Hans-Joachim Galla and Tanja Schwerdtle

J. Biol. Chem. published online March 28, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.344093

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2012/03/28/jbc.M112.344093.full.html#ref-list-1